1 / 27

Graft Versus Host Disease

Graft Versus Host Disease. Criteria for Development of GVHD. Graft contains immunologically competent cells Host appears foreign to the graft; it has alloantigens that are capable of antigenically stimulating the graft

dena
Download Presentation

Graft Versus Host Disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Graft Versus Host Disease

  2. Criteria for Development of GVHD • Graft contains immunologically competent cells • Host appears foreign to the graft; it has alloantigens that are capable of antigenically stimulating the graft • Host is unable to mount an effective immunological reaction against the graft

  3. Patients at High Risk for GVHD • Allogeneic & autologous hematopoietic cell transplantation (age, HLA disparity, gender disparity, allosensitized donor) • Solid organ transplantation (liver, small bowel) • Transfusion of unirradiated blood products (fetuses, neonates, immunodeficiency syndromes, chemoradiotherapy)

  4. Pathophysiology of GVHD – 3 stages • Damaged host tissue cytokines (TNFα, IL1) stimulate APCs recognition of host Ag by donor T cell • Donor T cell activated cytokines (IFNγ, IL2) induce CTL, NKC, phagocytes • Phagocytes release more cytokines cell lysis/apoptosis tissue destruction

  5. Pathophysiology of GVHD

  6. 2 Types of GVHD • Acute (10-30 days posttransplant) - triad of derm, hepatic, and GI manifestations (barriers to infection thus APCs) - 40-80% incidence (depends on HLA match) • Chronic ( >100 days posttransplant) - diverse range of affected organ systems - 70-90% evolve from acute GVHD - 20% occur de novo - 10% occur after acute GVHD resolves

  7. Acute GVHD – Dermatological • Painful or pruritic erythematous macules of palms, soles, trunk, limbs • Confluent erythema, erythroderma and/or papule formation • Subepidermal bullae and vesicle formation • Stages 1-4 based on % BSA involved and presence of bullae/vesicles

  8. Acute GVHD – Dermatological • Boy who developed stage 3 skin involvement with acute graft versus host disease despite receiving prophylaxis with cyclosporin A. The donor was a sister matched for human leukocyte antigen. The gender disparity increased the risk for acute graft versus host disease.

  9. Acute GVHD – Hepatic • Asymptomatic elevations in bilirubin, ALT, AST, alkaline phosphatase similar to cholestatic jaundice

  10. Acute GVHD – GI • Anorexia • Dyspepsia • Cramping abdominal pain • Diarrhea (secretory diarrhea may persist despite NPO) • Intestinal bleeding • Ileus

  11. Chronic GVHD - Dermatological • Same as acute GVHD • Atrophy and erythema of oral mucosa • Lichenoid lesions of skin, buccal and labial mucosa • Sclerodermatous skin thickening • Joint contractures

  12. Chronic GVHD – Ocular • Keratoconjunctivitis sicca may lead to corneal erosions • Hemorrhagic conjunctivitis • Pseudomembrane formation • Lagophthalmos

  13. Chronic GVHD – Pulmonary • Obstructive lung disease • Dyspnea, wheezing, chronic cough • Nonresponsive to bronchodilators • Bronchiolitis obliterans

  14. Chronic GVHD – GI • Same as acute GVHD • Sensitivity to acidic or spicy foods • Odyno/Dysphagia • Esophageal strictures or dysmotility • Weight loss

  15. Chronic GVHD – Hepatic • Same as acute GVHD • Hyperbilirubinemia – jaundice, pruritis and excoriations • Portal HTN, cirrhosis, and hepatic failure are rare

  16. Chronic GVHD – Neuromuscular • Weakness • Neuropathic pain • Muscle cramps • Symptoms may resemble myasthenia gravis or polymyositis

  17. Chronic GVHD – Misc. • Many similarities to autoimmune disorders • SLE • Sjogren syndrome • Rheumatoid arthritis • Primary biliary cirrhosis • Lichen planus

  18. Prevention • Depletion of T cells from donor has reduced the incidence of GVHD, however, this results in increased incidence of graft failure and malignancy occurrence • Leukemic cells may have specific antigen profiles that make them susceptible to the GVL effect.

  19. Graft vs. Leukemia Effect • Mortality of GVHD with no leukemic relapse vs. mortality of leukemic relapse and no GVHD is under investigation

  20. Prophylactic Treatment • Cyclosporine (CSP) + Methotrexate (MTX) +/- Prednisone 180 days • Tacrolimus (Prograf) + MTX 180 days • IVIG for antibody prophylaxis Qweek x12 (good for acute , not chronic)

  21. Primary Treatment for Acute GVHD • CSP or Prograf + methylprednisolone (MP) • Antihymocyte globulin (ATG) • Mycophenolate mofetil (CellCept) • Anti-CD5 immunotoxin • XomaZyme – pan T cell immunotoxin

  22. Secondary Treatment for Acute GVHD • ATG • Increased MP doses • Muromonab-CD3 • IL-1 receptor antagonist • Conversion from CSP to Prograf • Psoralen +UVA light (PUVA) for cutaneous GVHD

  23. Primary Treatment for Chronic GVHD • Prednisone 1 mg/kg QOD +/- CSP • Thalidomide

  24. Secondary Treatment for Chronic GVHD • Azathioprine (Imuran) • Alternating CSP & Prednisone • Thalidomide • Clofazimine (antileprosy agent) and PUVA for cutaneous GVHD

  25. Prognosis • Acute GVHD: response to tx 25% mortality vs. 75% mortality with no response or progression. • Chronic GVHD: 6 yr. mortality is 58% overall and 90% for progressive disease. • Mortality for both acute and chronic GVHD is mostly due to sepsis. • Higher mortality in patients with HLA mismatched donor, bilirubin > 2 mg/dL, thrombocytopenia, lichenoid skin histology, high dose prednisone.

  26. References • Fleming DR, Graft-vs-host disease: what is the evidence? Evidence-based Oncology 2002; 3. • Mandanas RA, et al. Graft versus host disease. Emedicine.com/med/topic926. • Hoffman: Hematology: Basic Principles and Practice, 3rd ed., 2000. • Kuechle MK, et al. Graft versus host disease. Emedicine.com/derm/topic478.

More Related